Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 Study

Post time 2024-6-17 17:42:42

journal：Clinical Lymphoma Myeloma and Leukemia

Authors：Albert Oriol; Roman Hájek; Ivan Spicka; Irwindeep Sandhu; Yael C. Cohen; Moshe E. Gatt; José Mariz; Michele Cavo; Jesús Berdeja; Kexin Jin; Merav Bar; Prianka Das; Ross La Motte-Mohs; Yu Wang; Deepak Perumal; Luciano J. Costa

Published date：2024-5-

DOI：10.1016/j.clml.2024.05.014

PDF link：https://www.sciencedirect.com/sc ... 152265024002003/pdf

Article link：http://dx.doi.org/10.1016/j.clml.2024.05.014

Article Source：Elsevier BV。

Remark：

Post time 2024-6-17 17:42:43

: This post has been completed
Completed attachments will be deleted within 24 hours.

Post time 2024-6-17 18:02:41

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Elsevier] Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 Study

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today